CVS Health is launching a new company that will work directly with drug makers to produce and commercialize “biosimilar” drugs, the less expensive versions of expensive brand prescriptions derived from biotechnology.
Biosimilars are versions of biologic medicines approved by the U.S. Food and Drug Adminstration that are “highly similar to” and have “no clinically meaningful differences from” brand biologic medicines already on the market, CVS said.
Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação: